DKDaniel Kaemmerer

Daniel Kaemmerer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Kaemmerer has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surgery in combination with peptide receptor radionuclide therapy is effective in metastatic neuroendocrine tumors and is definable by blood gene transcript analysis.

    by Andreja Frilling, Daniel Kaemmerer, Mark S. Kidd, Ashley K Clift, Justin Stebbing, Richard P. Baum, Leandro Castellano, Harpreet Singh Wasan, Irvin Mark Modlin

    E15697 Background: Neuroendocrine tumours (NET) of the pancreas (PNET) or small bowel (SBNET) frequently present with metastases at initial diagnosis, undermining the efficacy of surgical treatment. Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, has been shown to achieve prolonged progression-free survival (PFS) in a substantial number of non-surgical patients with advanced NET. Our aim was to prospectively determine the efficacy of a combination of radical loco-regional surgery and PRRT in patients with metastasised NET. Methods: A set of inclusion criteria was defined (e.g. G1/G2 NET, initial tumour diagnosis, treatment naïve patient, stage IV NET, positivity on 68Ga DOTA- PET/CT, eligibility for surgery and PRRT). Patients underwent PRRT within 3 months following surgery. Follow-up included biochemistry and imaging. In a sub-cohort, blood-based neuroendocrine gene transcript analysis of 51 genes (NETest) was used to define the effectiveness of treatment. Outcome measures included 5-year overall survival (OS) and PFS from initial diagnosis. Results: Twenty-five patients (5 PNET, 20 SBNET) met eligibility criteria and were included. There were 13 men (52%) and mean age was 57.1 years. All patients with SB NET underwent right hemicolectomy, terminal ileal resection and mesenteric lympadenectomy. In all PNET patients only limited pancreatic resection was required. The median number of PRRT cycles was 4 (range 2-6). Post-treatment mortality was 0%. Surgical morbidity was 12% (all Clavien-Dindo grade 1). Transient grade 1 toxicity occurred post-PRRT in 40%. NETest scores were increased in 8 patients (100%) pre-operatively and decreased in all following treatment. NETest decreases correlated with diminished tumour volume (R2=0.37, p=0.02). Median follow-up was 48 months (range 12-72months). Five-year OS was 90% and 5-year PFS was 84.3%. Conclusions: Radical loco-regional surgery for primary tumours combined with PRRT provides a novel, highly efficacious approach in metastasised NET. The NETest accurately measures the effectiveness of treatment.

  • Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas

    by Daniel Kaemmerer, Joerg Saenger, Ruza Arsenic, Jan G. D'Haese, Jens Neumann, Aviral Singh, Richard P. Baum, Stefan Schulz, Amelie Lupp

    Background: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed. Aims: In the present study the expression of the five somatostatin receptor (SSTR) subtypes as well as of the chemokine receptor CXCR4 and of the endothelin receptor A (ETA) was evaluated. Methods: Receptor expression was assessed by means of immunohistochemistry using a panel of novel rabbit monoclonal antibodies in a total of 54 paraffin-embedded paraganglioma tumor samples from 43 patients. The stainings were rated by means of the Immunoreactive Score and correlated to clinical data. Results: The SSTR2 was by far the most prominent receptor in the paragangliomas investigated. It was present in all samples at a high intensity, followed by the SSTR5, the SSTR1, the SSTR3 and the SSTR4. The CXCR4 and the ETA were seen only in a few cases on the tumor cells. However, with respect to the tumor blood vessels, in all cases an exceptionally strong staining for the ETA and in the majority of the samples also for the CXCR4 was noticed. Conclusions: Due to the high expression rate found in the present study, paragangliomas seem to be well suited for SSTR2-based diagnostics and therapies. Additionally, an indirect targeting of these highly vascularized tumors via the CXCR4 or the ETA may represent a promising future strategy.

  • Localization of Radiolabeled Somatostatin Analogs in the Spleen

    by Marleen Melis, Daniel Kaemmerer, Jan de Swart, Harshad R. Kulkarni, Amelie Lupp, Jörg Sänger, Harald C. Groen, Mark W. Konijnenberg, Marion de Jong, Richard P. Baum

    Radiolabeled somatostatin (SST) analogs, used to visualize and treat SST receptor (SSTR)-expressing neuroendocrine tumors, also accumulate in the spleen. There is a high interpatient variation and no significant radiation-induced splenic toxicity; however, an absorbed dose-related reduction in spleen size was detected. However, the exact localization of radioactivity and the role of SST receptors in splenic retention are unknown. Therefore, we performed ex vivo micro-SPECT of the isolated spleen from a patient with a pancreatic neoplasm after 1 GBq (27 mCi) Lu-DOTATATE administration, followed by autoradiography and immunohistochemistry. Ex vivo autoradiography demonstrated convincingly that most radioactivity accumulated in red pulp.


  • Open Access

    Treatment of osteoporosis after liver transplantation with ibandronate

    by Daniel Kaemmerer, Gabriele Lehmann, Gunter Wolf, Utz Settmacher, Merten Hommann

    Osteoporosis is a major side‐effect after liver transplantation (LTX). Therefore, the objective of the study was to evaluate the efficacy of ibandronate to reduce fractures after LTX. Seventy‐four patients after LTX were included in the study and measurements of bone mineral density (BMD) of lumbar spine and proximal femur using dual energy X‐ray absorptiometry (DEXA) were performed prior to and 3, 6, 12 and 24 months after surgery. The study group (IBA) consisted of 34 patients who received calcium (1 g/day), vitamin D3 (800–1000 IE/day) and ibandronate 2 mg every 3 months intravenously for 1 year. The control group consisted of 40 patients (CON) who received calcium and vitamin D3 at the same dosages. Prevalence of new fractures was predefined as primary endpoint. Changes of BMD and biochemical markers of bone metabolism were also investigated. In all patients, we found a reduction of BMD in the first few months after LTX. In the lumbar spine and the proximal femur the maximum reduction occurred 3 and 6 months post‐LTX. One and 2 years after transplantation, the group receiving ibandronate demonstrated a better recovery from loss of BMD and a significantly lower prevalence of fractures (IBA 2 vs. CON 10 P < 0.04, χ2). Ibandronate with calcium and vitamin D3 reduces the BMD‐loss after LTX and decreases the rate of bone fractures significantly.


  • Open Access

    Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor

    by Daniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, Dieter Hörsch, Günter Klöppel, Merten Hommann, Richard P Baum

    Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor